A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
Conditions: Salmonella Infections Interventions: Biological: Measles and Rubella vaccine; Biological: Yellow Fever vaccine; Biological: Pentavalent vaccine; Biological: Pneumococcal vaccine; Biological: Inactivated polio vaccine; Biological: iNTS-GMMA Dose C; Biological: iNTS-GMMA Dose B; Biological: iNTS-GMMA Dose A; Biological: MenACWY; Combination Product: DTPa-HBV-IPV+Hib; Drug: Placebo Sponsors: GlaxoSmithKline; European& Developing Countries Clinical Trials Partnership; Kwame Nkrumah University of Science and Technology; Pedvac iNTS consortium Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Children | Clinical Trials | Measles | Measles Vaccine | Men | Meningitis Vaccine | Partnerships | Pneomococcal Vaccine | Polio | Polio Vaccine | Research | Rubella | Rubella Vaccine | Salmonella | Science | Study | Vaccines | Yellow Fever | Yellow Fever Vaccination